



## Clinical trial results:

### **A Phase 2a, Randomised, Double-Blind, Placebo-Controlled, Two-Part Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetic Profiles of Inhaled Doses of NOC-100 in Adult Participants with Chronic Cough or Acute Cough, including Cough due to Postinfectious COVID-19**

#### **Summary**

EudraCT number	2020-004715-27
Trial protocol	DE
Global end of trial date	06 November 2023

#### **Results information**

Result version number	v1 (current)
This version publication date	14 December 2024
First version publication date	14 December 2024

#### **Trial information**

##### **Trial identification**

Sponsor protocol code	NOC100-C-201
-----------------------	--------------

##### **Additional study identifiers**

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	-
WHO universal trial number (UTN)	-

Notes:

##### **Sponsors**

Sponsor organisation name	Nocion Therapeutics, Inc.
Sponsor organisation address	15 Main Street, #247, Watertown, United States, MA 02472
Public contact	Clinical Trials Information, Nocion Therapeutics, Inc., +1 617803 2445, clinicaltrials@nociontx.com
Scientific contact	Clinical Trials Information, Nocion Therapeutics, Inc., +1 617803 2445, clinicaltrials@nociontx.com

Notes:

##### **Paediatric regulatory details**

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	27 June 2023
Is this the analysis of the primary completion data?	Yes
Primary completion date	04 May 2022
Global end of trial reached?	Yes
Global end of trial date	06 November 2023
Was the trial ended prematurely?	Yes

Notes:

## General information about the trial

Main objective of the trial:

Part 1:

To evaluate the safety and tolerability of escalating nebulised inhaled doses of NOC 100 (single and 2 consecutive QD doses) in participants with chronic cough (CC).

Part 2:

To evaluate the treatment effect of nebulised inhaled doses of NOC 100 as determined by visual analogue scale (VAS) score for cough severity in participants with acute cough (AC).

To evaluate the safety and tolerability of nebulised inhaled doses of NOC 100 in participants with AC.

Protection of trial subjects:

Prior to initiation of any study-specific procedures, participants received a copy of the Informed Consent Form (ICF) that summarized, in non-technical terms, the purpose of the study, the procedures to be carried out, and the potential hazards. The Principal Investigators (PIs) or their representatives explained the nature of the study to the participants, in non-technical terms, and answered all questions regarding the study. Participants reviewed, signed, and dated the ICF. Participants received a copy of the fully signed ICF.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	29 April 2021
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	United Kingdom: 21
Country: Number of subjects enrolled	Germany: 20
Worldwide total number of subjects	41
EEA total number of subjects	20

Notes:

### Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0

Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	23
From 65 to 84 years	18
85 years and over	0

## Subject disposition

### Recruitment

Recruitment details: -

### Pre-assignment

Screening details:

Adult male and females with chronic cough were screened against the eligibility criteria between 28 to 7 days prior to Day -2.

### Period 1

Period 1 title	Overall study (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator, Monitor

### Arms

Are arms mutually exclusive?	No
<b>Arm title</b>	NOC-100

Arm description:

Subjects randomized to receive NOC-100

Arm type	Experimental
Investigational medicinal product name	NOC-100 Nebulized Solution
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Nebuliser solution
Routes of administration	Inhalation use

Dosage and administration details:

NOC-100 nebulized solution was administered via nebulizer for 2 consecutive days at each of 3 dose levels sequentially with 4 days wash-out in between.

<b>Arm title</b>	Placebo
------------------	---------

Arm description:

Subjects randomized to receive placebo.

Arm type	Placebo
Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Nebuliser solution
Routes of administration	Inhalation use

Dosage and administration details:

Matching placebo nebulized solution was administered via nebulizer for 2 consecutive days at each of 3 dosing periods with 4 days wash-out in between.

<b>Number of subjects in period 1</b>	NOC-100	Placebo
Started	41	38
Completed	37	37
Not completed	4	1
Consent withdrawn by subject	1	-
Physician decision	1	-
Adverse event, non-fatal	2	1

## Baseline characteristics

### Reporting groups

Reporting group title	Overall study
-----------------------	---------------

Reporting group description: -

Reporting group values	Overall study	Total	
Number of subjects	41	41	
Age categorical			
Units: Subjects			
In utero		0	
Preterm newborn infants (gestational age < 37 wks)		0	
Newborns (0-27 days)		0	
Infants and toddlers (28 days-23 months)		0	
Children (2-11 years)		0	
Adolescents (12-17 years)		0	
Adults (18-64 years)		0	
From 65-84 years		0	
85 years and over		0	
Age continuous			
Units: years			
arithmetic mean	59.7		
standard deviation	± 10.91	-	
Gender categorical			
Units: Subjects			
Female	37	37	
Male	4	4	

## End points

### End points reporting groups

Reporting group title	NOC-100
Reporting group description: Subjects randomized to receive NOC-100	
Reporting group title	Placebo
Reporting group description: Subjects randomized to receive placebo.	

### Primary: Adverse events

End point title	Adverse events <sup>[1]</sup>
End point description:	
End point type	Primary
End point timeframe: Treatment Emergent Adverse Events were recorded from first dose until last study visit.	

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Per protocol, the primary endpoint was the incidence of safety events, consequently, no additional formal statistical analyses were performed on primary endpoint data in this early phase study.

End point values	NOC-100	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	41	38		
Units: Subjects				
Subjects with TEAEs	20	16		
Subjects without TEAEs	21	22		

### Statistical analyses

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

From first dose to end of study visit.

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	23.1
--------------------	------

### Reporting groups

Reporting group title	NOC-100
-----------------------	---------

Reporting group description:

Subjects randomized to receive NOC-100

Reporting group title	Placebo
-----------------------	---------

Reporting group description:

Subjects randomized to receive placebo

<b>Serious adverse events</b>	NOC-100	Placebo	
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 41 (0.00%)	0 / 38 (0.00%)	
number of deaths (all causes)	0	0	
number of deaths resulting from adverse events	0	0	

Frequency threshold for reporting non-serious adverse events: 0 %

<b>Non-serious adverse events</b>	NOC-100	Placebo	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	20 / 41 (48.78%)	16 / 38 (42.11%)	
Injury, poisoning and procedural complications			
Joint dislocation			
subjects affected / exposed	1 / 41 (2.44%)	0 / 38 (0.00%)	
occurrences (all)	1	0	
Ligament sprain			
subjects affected / exposed	0 / 41 (0.00%)	1 / 38 (2.63%)	
occurrences (all)	0	1	
Vascular disorders			

Hypotension subjects affected / exposed occurrences (all)	1 / 41 (2.44%) 1	2 / 38 (5.26%) 2	
Phlebitis subjects affected / exposed occurrences (all)	1 / 41 (2.44%) 1	0 / 38 (0.00%) 0	
Cardiac disorders			
Atrial fibrillation subjects affected / exposed occurrences (all)	1 / 41 (2.44%) 1	1 / 38 (2.63%) 1	
Bradycardia subjects affected / exposed occurrences (all)	2 / 41 (4.88%) 2	0 / 38 (0.00%) 0	
Supraventricular extrasystoles subjects affected / exposed occurrences (all)	1 / 41 (2.44%) 1	0 / 38 (0.00%) 0	
Supraventricular tachycardia subjects affected / exposed occurrences (all)	0 / 41 (0.00%) 0	1 / 38 (2.63%) 1	
Nervous system disorders			
Head discomfort subjects affected / exposed occurrences (all)	1 / 41 (2.44%) 1	0 / 38 (0.00%) 0	
Headache subjects affected / exposed occurrences (all)	6 / 41 (14.63%) 6	4 / 38 (10.53%) 4	
Migraine subjects affected / exposed occurrences (all)	0 / 41 (0.00%) 0	1 / 38 (2.63%) 1	
Presyncope subjects affected / exposed occurrences (all)	0 / 41 (0.00%) 0	1 / 38 (2.63%) 1	
Tension headache subjects affected / exposed occurrences (all)	0 / 41 (0.00%) 0	1 / 38 (2.63%) 1	
General disorders and administration site conditions			

Catheter site swelling subjects affected / exposed occurrences (all)	1 / 41 (2.44%) 1	0 / 38 (0.00%) 0	
Malaise subjects affected / exposed occurrences (all)	1 / 41 (2.44%) 1	0 / 38 (0.00%) 0	
<b>Gastrointestinal disorders</b>			
Diarrhoea subjects affected / exposed occurrences (all)	1 / 41 (2.44%) 1	1 / 38 (2.63%) 1	
Dysphagia subjects affected / exposed occurrences (all)	0 / 41 (0.00%) 0	2 / 38 (5.26%) 2	
Enteritis subjects affected / exposed occurrences (all)	1 / 41 (2.44%) 1	0 / 38 (0.00%) 0	
Haematochezia subjects affected / exposed occurrences (all)	0 / 41 (0.00%) 0	1 / 38 (2.63%) 1	
Nausea subjects affected / exposed occurrences (all)	2 / 41 (4.88%) 2	1 / 38 (2.63%) 1	
Paraesthesia subjects affected / exposed occurrences (all)	1 / 41 (2.44%) 1	0 / 38 (0.00%) 0	
Salivary hypersecretion subjects affected / exposed occurrences (all)	0 / 41 (0.00%) 0	1 / 38 (2.63%) 1	
Stomatitis subjects affected / exposed occurrences (all)	0 / 41 (0.00%) 0	1 / 38 (2.63%) 1	
Vomiting subjects affected / exposed occurrences (all)	4 / 41 (9.76%) 4	0 / 38 (0.00%) 0	
<b>Respiratory, thoracic and mediastinal disorders</b>			

Cough subjects affected / exposed occurrences (all)	11 / 41 (26.83%) 11	11 / 38 (28.95%) 11	
Pharyngeal hypoaesthesia subjects affected / exposed occurrences (all)	2 / 41 (4.88%) 2	0 / 38 (0.00%) 0	
Pharyngeal paraesthesia subjects affected / exposed occurrences (all)	1 / 41 (2.44%) 1	0 / 38 (0.00%) 0	
Skin and subcutaneous tissue disorders Rash subjects affected / exposed occurrences (all)	0 / 41 (0.00%) 0	1 / 38 (2.63%) 1	
Renal and urinary disorders Pollakiuria subjects affected / exposed occurrences (all)	0 / 41 (0.00%) 0	1 / 38 (2.63%) 1	
Musculoskeletal and connective tissue disorders Arthralgia subjects affected / exposed occurrences (all)	1 / 41 (2.44%) 1	1 / 38 (2.63%) 1	
Periarthritis subjects affected / exposed occurrences (all)	0 / 41 (0.00%) 0	1 / 38 (2.63%) 1	
Limb discomfort subjects affected / exposed occurrences (all)	0 / 41 (0.00%) 0	1 / 38 (2.63%) 1	
Infections and infestations Abscess subjects affected / exposed occurrences (all)	1 / 41 (2.44%) 1	0 / 38 (0.00%) 0	
asymptomatic COVID-19 subjects affected / exposed occurrences (all)	0 / 41 (0.00%) 0	1 / 38 (2.63%) 1	
COVID-19			

subjects affected / exposed occurrences (all)	2 / 41 (4.88%) 2	0 / 38 (0.00%) 0	
Cystitis subjects affected / exposed occurrences (all)	0 / 41 (0.00%) 0	1 / 38 (2.63%) 1	
Urinary tract infection subjects affected / exposed occurrences (all)	1 / 41 (2.44%) 1	0 / 38 (0.00%) 0	
Viral upper respiratory tract infection subjects affected / exposed occurrences (all)	0 / 41 (0.00%) 0	1 / 38 (2.63%) 1	

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
11 January 2021	Version 2 of the study protocol was prepared to address comments and recommendations of the BfArM and Ethics.
05 February 2021	Version 3 of the study protocol was prepared to address comments and recommendations of the BfArM and Ethics.
05 November 2021	Version 4 of the protocol was requested by the Sponsor and included updates to the following: study contacts, number of study participants, washout duration, safety assessments, inclusion and exclusion criteria, and Bitrex(R) administration.

Notes:

---

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.

The number of occurrences of each adverse event was not detailed in the Clinical Study Report - this has been entered as equal to the number of subjects reporting each event.

Notes: